Achieve Life Sciences announced its second-quarter 2026 financial results on August 10, 2026. The clinical-stage pharmaceutical company is currently advancing its lead product candidate, cytisinicline, for smoking cessation and nicotine addiction.
The company appointed new leadership for its manufacturing, supply chain, and quality departments on August 3, 2026. These appointments support the strategic transition of manufacturing operations to the United States.
This corporate shift follows a June 2026 Complete Response Letter from the FDA regarding the New Drug Application for cytisinicline. The FDA previously cited deficiencies at a third-party manufacturing facility as the primary reason for the rejection.